- evidence synthesis
- dynamic transmission
- calibration/validation
- approaches and applications
- decision analysis
- risk analysis
- benefit-cost analysis
- cost-effectiveness analysis
- technology assessment
- operations research
- child/nutrition
- chronic disease/risk
- social determinants
- health/medicine
- global
- latin america & caribbean
- asia & pacific
Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global | Social Determinants | Chronic Disease/Risk | Child/Nutrition | Costing Methods | Health Outcomes | Infectious Diseases | Maternal/Reproductive Health | Mental Health | Injuries/Accidents | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Science/Technology -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Calibration/Validation | Health/Medicine | Asia & Pacific | Latin America & Caribbean | Global | Chronic Disease/Risk | Health Outcomes | Mathematical Models | Infectious Diseases | Health Systems | Sub-Saharan Africa | Middle East & North Africa -
ReportPublication 2017DCP3: Child and Adolescent Health and Development
This report from the World Bank is the eighth volume of the Disease Control Priorities, …
This report from the World Bank is the eighth volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on the health and well-being of children and adolescents, ages 5 to 21, worldwide. It provides estimates of mortality and morbidity among youth, examines the impact of interventions during that period on health and development, features successful community- and school-based health and nutrition interventions, reports on platforms that promote early childhood development, and highlights…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Global | Social Determinants | Child/Nutrition | Costing Methods | Health Outcomes | Global Governance | Economics/Finance -
ReportPublication 2017DCP3: Cardiovascular, Respiratory, and Related Disorders
This report from the World Bank is the fifth volume of the Disease Control Priorities, …
This report from the World Bank is the fifth volume of the Disease Control Priorities, Third Edition (DCP3) series. It addresses the disease burden of cardiovascular, respiratory, and related disorders (CVRDs), which account for more than half of global adult deaths, mostly in low- and middle-income countries. While CVRDs are mostly preventable or can be treated to reduce morbidity, such interventions are costly and require greater capacity to detect and treat early. When combined with…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Global | Social Determinants | Chronic Disease/Risk | Costing Methods | Health Outcomes | Health Systems | Global Governance | Climate/Environment -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Dynamic Transmission | Health/Medicine | Asia & Pacific | Latin America & Caribbean | Child/Nutrition | Health Outcomes | State-Transition | Microsimulation | Infectious Diseases | Health Systems | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Dynamic Transmission | Health/Medicine | Asia & Pacific | Latin America & Caribbean | Child/Nutrition | Mathematical Models | Infectious Diseases | Health Systems | Global Governance | Climate/Environment | Economics/Finance -
ArticlePublication 2019Impact of a Tax on Sweetened Beverages in the Philippines: an ECEA
This study used extended cost-effectiveness analyses to estimate the effect of the sweetened beverages tax …
This study used extended cost-effectiveness analyses to estimate the effect of the sweetened beverages tax in the Philippines on the numbers of premature deaths averted attributed to type 2 diabetes mellitus, ischemic heart disease and stroke, across income quintiles over the period 2018-2037. The study also estimated the financial benefits of the tax from reductions in out-of-pocket payments, direct medical costs averted, and government health-care cost savings. The analysis showed that the tax could avert…
Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific | Social Determinants | Chronic Disease/Risk | Child/Nutrition | Priority Setting/Ethics | Mathematical Models | Policy/Regulation -
ArticlePublication 2017Cost-Effectiveness of a Policy Strategy to Decrease Sodium Intake: Global Analysis
The objective of this study was to assess the cost effectiveness of a government policy combining …
The objective of this study was to assess the cost effectiveness of a government policy combining targeted industry agreements and public education to reduce sodium intake in 183 countries worldwide. To account for heterogeneity in efficacy across countries, a range of scenarios were evaluated, including 10%, 30%, 0.5 g/day, and 1.5 g/day sodium reductions achieved over 10 years. Country specific costs of a sodium reduction policy were estimated using the WHO Noncommunicable Disease Costing Tool. Country…
Cost-Effectiveness Analysis | Health/Medicine | Global | Social Determinants | Chronic Disease/Risk | Child/Nutrition | Policy/Regulation | Food/Agriculture | Government/Law -
ArticlePublication 2022Health and Financial Risk Protection Outcomes in Economic Evaluations
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution …
Extended cost-effectiveness analysis was developed to evaluate health interventions in terms of level and distribution of health gains and financial risk protection. This information is typically presented in a joint display format. This article develops and applies an algebraic money-metric formulation that incorporates all disaggregated outcomes and finds that ranking of health interventions is sensitive to the decision maker’s aversion to inequality across income groups and that financial risk protection gains are most important to…
Cost-Effectiveness Analysis | Health/Medicine | Global | Social Determinants | Chronic Disease/Risk | Priority Setting/Ethics | Economics/Finance